Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with <i>KRAS</i> Mutations-A Comprehensive Review and Description of Single Site Experience.

Cancers (Basel) · 2023 · PMC10378665 · PMID 37509393

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, a nonsignificant trend towards worse survival was noted in patients treated with ICIs whose tumors harbored the KRAS G12C variant compared to those with wild-type KRAS gene [ 65 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.